Novartis AG (NVS)
| Market Cap | 208.99B |
| Revenue (ttm) | 51.72B |
| Net Income (ttm) | 11.94B |
| Shares Out | 1.98B |
| EPS (ttm) | 5.87 |
| PE Ratio | 18.76 |
| Forward PE | 13.15 |
| Dividend | $3.28 (2.98%) |
| Ex-Dividend Date | Mar 12, 2025 |
| Volume | 1,826,910 |
| Open | 109.03 |
| Previous Close | 110.38 |
| Day's Range | 108.66 - 110.21 |
| 52-Week Range | 92.35 - 120.92 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 123.67 (+12.28%) |
| Earnings Date | Apr 29, 2025 |
About NVS
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Re... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NVS stock is "Hold." The 12-month stock price forecast is $123.67, which is an increase of 12.28% from the latest price.
News
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Phase III study showed sustained proteinuria reduction at one year with favorable safety1 Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C...
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta ® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis scraps use of diverse panels for hires in US
Swiss drugmaker Novartis is ending its use of diverse panels for all of its hiring in the United States, the company told Reuters on Wednesday, citing the changing legal and policy landscape surroundi...
Novartis CEO says it is watching US reciprocal tariff policy 'very carefully'
Swiss pharmaceutical giant Novartis says it is watching "very carefully" how the reciprocal tariff policy proposed by the United States would unfold in early April, Chief Executive Vas Narasimhan said...
Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032: Nantomics, Genentech, and Novartis are Pivotal in the Development of the $16.4 Billion Market
Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. A newly revealed compreh...
NFL signs Novartis as first pharmaceutical partner-source
The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based firm Novartis , a league source told Reuters on Thursday.
Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA Nephropathy
BOSTON, March 13, 2025 (GLOBE NEWSWIRE) -- Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initi...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
Basel, March 7, 2025 – Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the company's Annual General Meeting (AGM). A total of 1,693 shareh...
10 Dividend Aristocrat Bargains To Help You SWAN During This Trade War Turmoil
The trade war is causing market volatility, with stocks falling and bonds performing well as investors seek hedges against economic slowdown fears. Dividend aristocrats, particularly low-volatility, d...
Novartis not panicking over potential US pharmaceutical tariffs, chairman says
Novartis is not panicking about higher tariffs on pharmaceutical imports that U.S. President Donald Trump could impose, the drug maker's Chairman Joerg Reinhardt said in an interview published on Thur...
Final Trade: NVS, XLU, GM
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presented New analyses of 52-week data from Phase III ...
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
Basel, February 28, 2025 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended...
Why Novartis Remains A 'Buy' After Beating Expectations Again
At the end of January, Novartis pleasantly surprised me with its financial results for Q4 2024, which were achieved, in part, due to the strong performance of its oncology franchise. So, sales of Pluv...
Syngenta acquires genetic repository from Novartis to boost biologic crop protection
Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and genetic strains from drugmaker Novartis to further boost development of biologi...
Sandoz family foundation offers $3 billion worth of Novartis shares
Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 billion in an accelerated bookbuil...
Novartis Invests $7.5M to Promote Early Prostate Cancer Testing in Vulnerable Communities
Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for prostate cancer in vulnerable communities.
Novartis: Strong Execution With A P/E Discount
Q4 2024 results exceeded expectations with 16% net sales growth and a 55% increase in operating income, supporting Novartis' EPS growth trajectory. The acquisition of Anthos Therapeutics and strategic...
Novartis: Just What The Doctor Ordered
Novartis' robust drug pipeline and strong financials, including an AA- credit rating, support an 11% annual return expectation by 2027. The company's diverse blockbuster portfolio and strategic cost m...
Novartis agrees to acquire Anthos for up to $3.1 bln
Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant.
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion.
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company...
Novartis is considering further acquisitions to drive growth, CEO says
Novartis CEO Vas Narasimhan weighs in on the impact of the new U.S. administration and artificial intelligence on the pharmaceutical industry, as well as the possibility of further acquisitions.
Novartis AG (NVS) Q4 2024 Earnings Call Transcript
Novartis AG (NVS) Q4 2024 Earnings Call Transcript